Professional
Added to YB: 2024-01-24
Pitch date: 2024-01-24
EVO [bullish]
Evotec SE
-77.41%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Market Cap
EUR 612.5M
Pitch Price
EUR 14.86
Price Target
18.60 (+446%)
Dividend
N/A
EV/EBITDA
-11.42
P/E
-3.10
EV/Sales
0.87
Sector
Life Sciences Tools and Services
Category
value
Show full summary:
RBC upgrades $EVO to Outperform
$EVO at 5y low on CEO exit & share dealing probe; 8x 2025 EBITDA for double-digit grower looks cheap. Cyber attack & biotech funding headwinds, but BMS/Sandoz/DoD deals support biz. €18.6 PT has 20% risk discount; €23+ on strong 2025 EBITDA growth.
Read full article (2 min)